BEIGENE

BeiGene Corporate Presentation

March 25, 2021

BeiGene's Internal Pipeline

Three late-stage, and eight early-stage clinical assets

ASSETS	PROGRAMS	DOSE ESC. PH1a	DOSE EXPANSION PH1b	DOSE EXPANSION PH2*	PIVOTAL PH2**	PIVOTAL PH3	FILED	MARKET
zanubrutinib *(BTK)*	**monotherapy**	*R/R MCL (approved in multiple geographies)*						
		WM† (filings accepted in multiple geographies)						
		R/R MCL, R/R CLL/SLL (conditionally approved by NMPA in China 06.03.20)						
		R/R WM						
		1L CLL/SLL, R/R CLL/SLL						
		R/R MZL, lupus nephritis						
		Previously treated CLL/SLL (ibrutinib acalbrutinib intolerant)						
	combination	*+rituximab 1L MCL*						
		+obinutuzumab R/R FL						
		+lenalidomide +/- ritux. R/R DLBCL						
tislelizumab *(PD-1)*	**monotherapy**	*R/R cHL (approved 12.26.19), 2L+ UC (approved 04.10.20)*						
		2L/3L HCC, 2L/3L NSCLC						
		1L HCC, 2L ESCC, R/R cHL						
		R/R NK/T-cell lymphoma						
	+ chemo	*1L Sq. NSCLC (approved 01.13.21)*						
		1L non-Sq. NSCLC (sNDA accepted 06.19.20)						
		1L NPC, 1L SCLC, Stage II/IIIA NSCLC, Localized ESCC						
		1L GC, 1L ESCC						
	+ pamiparib *(PARP)* **+ zanubrutinib** *(BTK)*	*Solid tumors*						
		B-cell malignancies						
pamiparib *(PARP)*	**monotherapy**	*3L gBRCA+ OC*						
		2L platinum-sensitive OC maintenance						
		1L platinum-sensitive GC maintenance						
		HER2- BRCA mutated breast cancer						
		Solid tumors						
	+ TMZ *(chemo)*	*Solid tumors*						
	+ RT/TMZ *(RT/chemo)*	*Glioblastoma*						
ociperlimab (BGB-A1217, *TIGIT*)	**+ tislelizumab**	*1L NSCLC*						
		*R/M Cervical Cancer, R/M ESCC^*						
		Solid tumors						
lifirafenib *(RAF Dimer)*	**+ mirdametinib**	*B-Raf- or K-RAS/N-RAS-mutated solid tumors*						
BGB-A333 *(PD-L1)*	**monotherapy & + tislelizumab**	*Solid tumors*						
BGB-A425 *(TIM-3)*	**monotherapy & + tislelizumab**	*Solid tumors*						
BGB-A445 *(OX40)*	**+ tislelizumab**	*Solid tumors*						
BGB-11417 *(BCL-2)*	**monotherapy & + zanubrutinib**	*B-cell malignancies*						
BGB-10188 *(PI3-Kδ)*	**mono; + tislelizumab; + zanubrutinib**	*B-cell malignancies; Solid tumors*						
BGB-15025 *(HPK1)*	**monotherapy & + tislelizumab**	*Advanced solid tumors*						

*Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. **Confirmatory clinical trials post approval are required for accelerated approvals. † R/R or not suitable for chemo-immunotherapy; ^R/M: Recurrent / Metastatic

BeiGene's Collaborative Pipeline

China Global

COMPOUND	(TARGET) / PROGRAM	DOSE ESC.	DOSE EXPANSION		PIVOTAL		COMMERCIAL RIGHTS	PARTNER
		PH1a	PH1b	PH2*	PH2**	PH3		
Sotorasib	(KRAS G12C)	Solid Tumors, NSCLC, CRC					China	Amgen
AMG 701^^	(BCMA)	MM						
AMG 176	(Mcl-1, SM (i.v.))	Hematologic malignancies						
AMG 330^	(CD33)	Myeloid malignancies						
AMG 673^^	(CD33)	AML						
AMG 427^^	(FLT3)	AML						
AMG 757^^	(DLL3)	SCLC						
AMG 160^^	(PSMA)	Prostate cancer						
AMG 509^	(STEAP1 XmAb)	Prostate cancer						
AMG 199^^	(MUC17)	GC/GEJC						
AMG 910^^	(Anti-CLDN18.2)	GC/GEJC						
AMG 650	(oral small molecule)	Solid tumors						
AMG 506	(FAP x 4-1BB, DARPin®)	Solid tumors						
AMG 256	(Anti-PD-1 x IL21 mutein)	Solid tumors						
Sitravatinib†	(multi-kinase inhibitor) + tislelizumab	NSCLC, RCC, OC, MEL					Asia ex-Japan, AU, NZ	Mirati
	Mono, + tislelizumab	HCC, GC/GEJC						
Zanidatamab††	(HER2, bispecific antibody)	Breast cancer, GEA					Asia ex-Japan, AU, NZ	Zymeworks
		Biliary tract cancers						
ZW49	(HER2, bispecific ADC)	HER2-expressing cancers					Asia ex-Japan, AU, NZ	Zymeworks
BGB-3245[1]	(B-RAF)	Solid tumors					Asia ex-Japan	SpringWorks[1]
BA3017	(CTLA4) Mono, + tislelizumab	Tech transfer in progress					Global	BioAtla
SEA-CD70	(anti-CD70)	MDS, AML					Asia ex-Japan, AU, NZ	Seagen
DKN-01	(DKK1) + tislelizumab ± chemo	GC/GEJC					Asia ex-Japan, AU,NZ	Leap Therapeutics
ABI-H0731	(HBV core inhibitor)	Chronic Hepatitis B Virus					China	Assembly Bio
ABI-H2158	(HBV core inhibitor)	Chronic Hepatitis B Virus						
ABI-H3733	(HBV core inhibitor)	Chronic Hepatitis B Virus						

* Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. **Confirmatory clinical trials post approval are required for accelerated or conditional approvals. ^ BiTE, ^^ HLE BiTE, † Mirati is also conducting its own clinical studies with sitravatinib, including the Phase 3 SAPPHIRE trial in non-Sq NSCLC. †† ZW25, AML: acute myeloid leukemia, HLE BiTE: Half-life extended Bi-specific T-cell engagers, GC/GEJ: gastric cancer/gastroesophageal junction, HCC: hepatocellular carcinoma, IND: Investigational New Drug, MEL: melanoma, MM: multiple myeloma, NHL: non-Hodgkin's lymphoma, N/SCLC: non-/small cell lung cancer, OC: ovarian cancer, RCC: renal cell carcinoma, SM: small molecule; 1. By MapKure, a JV with SpringWorks